Day: October 6, 2021

Fort Lauderdale, Florida, Oct. 06, 2021 (GLOBE NEWSWIRE) — SFLMaven Corp. (OTC PINK: SFLM), (“SFLMaven” or the “Company”), a leading provider of high-end luxury goods, is pleased to report continued robust growth in its September performance metrics, including a powerful sequential monthly jump in revenues along with very strong web metrics at the Company’s online marketplace, which is rapidly approaching another major milestone in positive customer feedback. September sales came in at $1.1 million, up 32% on a sequential monthly basis. The Company also saw over 32 million web impressions at its online marketplace, with nearly 70% entirely organic. Page views also jumped on a month-over-month basis to more than 340k. The Company is also nearing a major milestone achievement as its eBay online storefront...

Glendale, CA, Oct. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Loop Media, Inc. (“Loop Media” or the Company) (OTC: LPTV), a leading multichannel streaming platform that provides curated music video and branded entertainment channels for businesses and consumers, announced today the appointment of Neil Watanabe as the Company’s Chief Financial Officer, to be effective September 30, 2021, in conjunction with Jim Cerna’s appointment to Head of Strategy, supporting several of the Company’s key strategic initiatives.  Prior to joining Loop, Mr. Watanabe was most recently Principal of Watanabe Associates where he provided senior financial and accounting leadership to various companies, including Value Village Inc. (d.b.a. “Savers”) and High Times Holding Corp. From 2015 to 2019 Mr. Watanabe was Chief Financial Officer of CarParts.com,...

Resonant’s XBAR® Technology to be Leveraged Across Additional Bands AUSTIN, Texas, Oct. 06, 2021 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, has expanded its multi-year commercial partnership with Murata Manufacturing Co., Ltd., the world’s largest RF filter manufacturer, for the development of 5G XBAR® RF filters. The expanded agreement targets RF filter designs utilizing Resonant’s proprietary XBAR® technology across additional bands. “Extending our agreement with Murata is a tremendous validation of our partnership and XBAR® technology as we continue working together to build a high-volume manufacturing platform,” said George B. Holmes, Chairman and CEO of Resonant. “Murata continues...

  As part of the agreement in principle on the future cooperation between Volvo Cars and Bilia on 1 October 2021 Bilia has signed a binding letter of intent to sell four facilities in Bergslagen to Bilkompaniet i Dalarna AB. The sale refers to the facilities in Avesta, Hedemora, Fagersta and Sala. These facilities conduct sales of new cars, used cars and service for Volvo and Renault. The sale is expected to take place on 1 January 2022. The parties will now begin final contract negotiations, which are expected to be completed in the autumn. The transfer is subject to approval by the Swedish competition authority. Gothenburg, October 6, 2021 Bilia AB (publ) For information please contact: Per Avander, Managing Director and CEO, +46 (0)10 497 70 00, per.avander@bilia.se  Kristina Franzén, CFO, +46 (0)10 497 73 40, kristina.franzen@bilia.se Facts...

Company’s Second AR Label Series Features Character Unlimited’s Iconic Fortune TellerJones Soda Brings Animated Zoltar Fortunes to Augmented Reality LabelsCompany’s Second AR Label Series Features Character Unlimited’s Iconic Fortune TellerCHICAGO, Oct. 06, 2021 (GLOBE NEWSWIRE) — Jones Soda Co. (OTCQB: JSDA) (“Jones Soda” or the “Company”), the original craft soda known for its unconventional flavors and user-designed label artwork, today announced a new series of augmented reality (“AR”) labels featuring the widely recognized fortune teller character Zoltar® reading humorous fortunes in short videos triggered by the Jones Soda app and a phone camera. The series follows last summer’s debut of Jones Soda AR labels showcasing extreme athletes and artists in action. Hitting store shelves in the U.S. and Canada...

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today the exportation of 30 kg of high-THC cannabis flower from its Portugal facility to Biopharmaceutical Research Company (“BRC”), a DEA-licensed pharmaceutical company that develops federally compliant active pharmaceutical ingredients (API) for plant-based therapeutics in the United States. Not only does this fortify Clever Leaves’ entrance into the U.S. and solidify BRC’s ability to transact internationally, but it positions the two organizations as some of the first companies ever to commercially ship dried cannabis flower from Portugal to the U.S. Under the agreement, Clever Leaves’ product, which...

MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer, will participate at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 4:30 p.m. ET. A live webcast of Dr. Marsolais’ presentation will be available through the ‘Events’ section of the Company’s investor relations website and will be archived for 90 days. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies...

FDA sets PDUFA target action date of June 5, 2022 NEWTON, Mass. and GENEVA, Oct. 06, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the treatment of patients with Urea Cycle Disorders (UCDs). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2022. Acer’s 505(b)(2) NDA is supported by results from two previously announced bioequivalence (BE) trials in which ACER-001 showed similar relative bioavailability for both phenylbutyrate (PBA) and phenylacetate (PAA), the active metabolite of sodium phenylbutyrate, compared...

Glendale, CA, Oct. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Loop Media, Inc. (“Loop Media” or the Company) (OTC: LPTV), a leading multichannel streaming platform that provides curated music video and branded entertainment channels for businesses and consumers, announced today that it has increased the size of its board of directors (the “Board”) to four and has appointed Denise M. Penz and Sonya Zilka as independent directors to fill the vacancies, with their appointment to become effective as of October 1, 2021. In connection with these director appointments, the Company will establish an Audit Committee, with Ms. Penz as Chairperson, a Compensation Committee, with Ms. Zilka as Chairperson, and a Nominating/Corporate Governance Committee. Loop Media is seeking to employ best practices for boards of directors in the...

First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s DiseaseA Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate Simufilam Over 78 Weeks In 1,000 Patients with Alzheimer’s DiseaseAUSTIN, Texas, Oct. 06, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today it has initiated an initial Phase 3 efficacy study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease. A second Phase 3 efficacy study of simufilam in Alzheimer’s disease is expected to begin by year end. Cassava Sciences’ Phase 3 efficacy studies of simufilam in Alzheimer’s disease are being conducted under Special Protocol Assessments (SPA) from the U.S. Food and Drug...